Intech Investment Management LLC Has $13.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Intech Investment Management LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 96.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,361 shares of the pharmaceutical company’s stock after acquiring an additional 16,873 shares during the quarter. Intech Investment Management LLC’s holdings in Vertex Pharmaceuticals were worth $13,457,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Vertex Pharmaceuticals by 1.0% in the third quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after purchasing an additional 243,088 shares in the last quarter. Geode Capital Management LLC lifted its position in Vertex Pharmaceuticals by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock worth $2,627,135,000 after buying an additional 166,987 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Vertex Pharmaceuticals by 10.7% during the 2nd quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock worth $1,949,228,000 after buying an additional 424,808 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Vertex Pharmaceuticals by 1.7% in the 2nd quarter. Loomis Sayles & Co. L P now owns 3,813,378 shares of the pharmaceutical company’s stock valued at $1,697,716,000 after acquiring an additional 65,047 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $1,593,974,000. 90.96% of the stock is owned by institutional investors.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 260 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $126,451.00. Following the transaction, the executive vice president owned 46,763 shares of the company’s stock, valued at approximately $22,743,185.05. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark E. Bunnage sold 620 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $301,537.00. Following the transaction, the executive vice president owned 7,284 shares in the company, valued at approximately $3,542,573.40. This trade represents a 7.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 168,937 shares of company stock valued at $77,879,922. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Profile of CEO Reshma Kewalramani in TIME highlights strong leadership and continued R&D momentum, which can support investor confidence in Vertex’s long-term pipeline and strategy. Article Title
• Positive Sentiment: Market commentary noting Vertex’s relative performance vs. the Dow suggests the stock still has investor interest and can attract momentum buyers after pullbacks. Article Title
• Neutral Sentiment: General coverage in Nasdaq-100 roundup pieces points to continued attention from index investors and analysts — useful for liquidity and index-fund flows but not an immediate catalyst. Article Title
• Neutral Sentiment: Recent Q4 results (Feb 12) showed revenue growth (~9.5% y/y) but a tiny EPS miss ($5.03 vs. $5.05 consensus). Fundamentals remain strong, but the small miss tempers near-term upside until forward guidance or pipeline news arrives. (Earnings release/public filings)
• Negative Sentiment: Multiple insider sales by several senior execs on Feb 25 — including large disposals such as EVP Duncan McKechnie (4,910 shares; ~21.9% reduction) and several other EVPs/CAO — collectively amount to roughly $4.6M in disclosed sales. Clustered insider selling can trigger short-term selling pressure and signals profit-taking or personal liquidity needs rather than company weakness, but markets often interpret heavy insider sales as a negative near-term indicator. SEC Filing (example)

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent analyst reports. Oppenheimer raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price target on the stock in a research report on Friday, February 13th. Wolfe Research raised Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective for the company in a report on Tuesday, January 6th. UBS Group boosted their target price on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Barclays upped their price target on shares of Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 17th. Finally, Evercore increased their price target on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $542.00.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $480.13 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The stock has a market cap of $121.97 billion, a price-to-earnings ratio of 31.32 and a beta of 0.30. The company has a fifty day moving average price of $465.74 and a two-hundred day moving average price of $431.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the prior year, the business posted $3.98 EPS. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.